

Serial No.: 10/633,843
RTS-0242US.C1

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound 8 to 50 nucleobases in length targeted to a coding region of a nucleic acid molecule encoding human superoxide dismutase 1, soluble (SEQ ID NO:3), wherein said compound comprises at least an 8- nucleobase ~~nuelebase~~ portion of ~~SEQ ID NO. 13~~ ~~or~~ SEQ ID NO. 15.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (canceled).

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Serial No.: 10/633,843
RTS-0242US.C1

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (canceled)

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claims 15-20 (canceled).

Serial No.: 10/633,843
RTS-0242US.C1

Claim 21 (new): An antisense oligonucleotide 8 to 50 nucleobases in length targeted to a coding region of a nucleic acid molecule encoding human superoxide dismutase 1, soluble (SEQ ID NO:3), wherein said compound comprises at least an 8-nucleobase portion of SEQ ID NO. 13 or SEQ ID NO. 15 and wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 22 (new): The compound of claim 21 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 23 (new): The compound of claim 22 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 24 (new): The compound of claim 22 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 25 (new): The compound of claim 22 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 26 (new): The compound of claim 25 wherein the modified nucleobase is a 5-methylcytosine.

Claim 27 (new): The compound of claim 22 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Serial No.: 10/633,843
RTS-0242US.C1

Claim 28 (new): A composition comprising the compound of claim 22 and a pharmaceutically acceptable carrier or diluent.

Claim 29 (new): The composition of claim 22 further comprising a colloidal dispersion system.

Claim 30 (new): The composition of claim 22 wherein the compound is an antisense oligonucleotide.